ClinicalTrials.gg
RecruitingNCT07466784CEDRN OUDUpdated Mar 12, 2026

CEDRN: Opioid Registry

An observational study in Opioid Use Disorder, Opioid Abuse or Dependence and Opioid Withdrawal, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University of British Columbia · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
7,200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Opioid-Related Disorders with a site in Canada — 11 open to participants now, 12 under way, 1 of them phase 3. Opioid-Related Disorders · Canada.

Started
2025
with 1 other
Observational
4 of 36
1 open now
Primary completion
2030-07
later than 11 of 11 live
Registered
34th of 36
by date
Lead sponsor
7 of 36
University of British Columbia

Among the 36 studies in Opioid-Related Disorders with a site in Canada, this one is one of 2 that started in 2025, is one of 4 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 34th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

11 of the 36 studies in Opioid-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Opioid-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

Unregulated opioids remain a leading driver of preventable mortality and potential years of life lost in Canada. Emergency departments (EDs)-open 24/7 and frequently accessed by people who use drugs-offer critical opportunities to reverse toxicity, mitigate harm, and initiate treatment. Yet, high quality evidence to guide ED care for patients with opioid poisoning and concomitant opioid dependence or opioid use disorder is limited. The investigators aim to establish a pan Canadian registry of patients presenting to EDs with opioid poisoning to generate timely, practice informing evidence. The investigators will create the Canadian Emergency Department Research Network (CEDRN) Opioid Registry across participating EDs nationwide. Using automated screening of electronic health records (EHRs), the investigators will identify consecutive patients of all ages with suspected or confirmed opioid poisoning at their index ED visit. The project's objectives are to establish a pan-Canadian registry of Emergency Department patients presenting with opioid poisoning, harmonize data collection across participating sites, describe variations in patient characteristics, clinical practice and outcomes, and derive a clinical decision rule to predict the risk of dying within 60 days. The expected outcomes include advancing healthcare delivery, improving patient and provider experiences, and enhancing population health and health system sustainability for individuals with opioid poisoning. This research is crucial for addressing the opioid crisis in Canada and has the potential to significantly impact patient care and outcomes.

Read the detailed description

Every day 21 Canadians die from opioid poisoning. Opioid poisoning deaths are predominantly driven by high potency, synthetic opioids (e.g. fentanyl, carfentanil) and other substances, which are highly addictive. Seven years after the toxic unregulated drug crisis was first declared a public health emergency, the human impact is staggering. More than 40,000 Canadians have lost their lives from opioid poisoning since 2016, most commonly people who are between 20 and 59 years old. Toxic illicit drugs have become the largest driver of potential years-of-life lost in our country. Emergency departments are frequented by people who use drugs. They are accessible 24-hours per day, 365-days per year without the need to schedule an appointment. Emergency department visits for substance use have increased, and more than half of patients who ultimately die from an opioid poisoning visit an emergency department in the year before they die, yet 20% of them leave against medical advice before their evaluation or treatment is complete. Among patients who leave against medical advice, 9% experience another episode of opioid poisoning within one week. Emergency department visits are opportunities to initiate treatment and connect people to harm reduction services, and may be the last chance to save a life. The main objectives are to:1) Harmonize data collection on patient and presentation characteristics, emergency department and in-hospital treatments and services, and the clinical course of patients who present to emergency departments with opioid poisoning and/or dependence across participating sites to create the CEDRN Opioid Registry; 2) Describe variation in and associations between presentations for opioid poisoning and/or dependence, clinical practice and patient outcomes including the safety and effectiveness of treatments and services geographically and over time; a) Determine the association between naloxone administration and precipitated opioid withdrawal (safety outcome) and time to opioid toxicity reversal (effectiveness outcome).b) Determine the association between buprenorphine/naloxone induction method and leaving against medical advice (safety outcome), and 30- and 60-day, and 3- and 12-month continued use of opioid agonist therapy and mortality (effectiveness outcomes).3) Derive a risk stratification tool to predict the risk of 60-day mortality in patients presenting to emergency departments with opioid poisoning and/or dependence to identify the highest risk patients for harm reduction services and treatments in our resource constrained environment. The investigators hypothesize that patient and/or visit characteristics will predict patient outcomes among patients presenting to emergency departments with opioid poisoning and/or dependence. Derivation of clinical decision rules to identify the highest risk patients will allow physicians to prioritize them for potentially life-saving treatments and services. The investigators also hypothesize that certain treatments or other variations in clinical practice will be associated with improved outcomes among patients presenting to emergency departments with opioid poisoning and/or dependence. These will be used to guide clinical care, decision-making and policy. The investigators will leverage existing infrastructure and governance to create a registry of consecutive eligible patients presenting to emergency departments with opioid poisoning and/or dependence. The investigators will create a single nationally-harmonized curated accessible dataset. It will capture the patient journey from ambulance arrival to hospital discharge filling critical gaps in administrative data, including individual-level sociodemographic variables, clinical signs and symptoms, investigations, pre-hospital, ED and hospital medications, interventions and clinical course. The investigators will include all patients who arrive at the emergency department and screen positive for opioid poisoning and/or dependence using the following screening criteria:1) Medication orders in the present or past (last 2 years) ED encounters: Buprenorphine, Buprenorphine-Naloxone, Methadone, Kadian, or Naloxone2) The following ED discharge diagnosis: Opioid overdose or intoxication, opioid withdrawal, overdoses of any of the following: Percocet, Oxycontin, Oxycodone, Overdose, Methadone, Heroin, Fentanyl, Codeine, Carfentanil3) Inpatient discharge diagnosis: Opioid use disorder (mild/moderate/severe, abuse/dependence), or opioid-related disorders. Adverse effect, and poisoning by polysubstance use. Opioid intoxication or withdrawal. Intoxication or withdrawal (from any substance, including unspecified ones). Adverse effect, and poisoning by opioids, benzodiazepines, other antiepileptic and sedative-hypnotic drugs, and unspecified drugs. Any psychoactive substance abuse resulting in intoxication, withdrawal, or any adverse effects. The investigators will include patients in cardiac arrest being resuscitated by paramedics on arrival and patients presenting without valid health care cards (e.g., comatose without an ID) using institution-assigned temporary IDs which are then assigned valid provincial health numbers. The investigators will track multiple visits by the same patient by assigning them the same Study ID using temporary (if needed) and provincial health numbers. The investigators will include patients with no fixed address and those who report staying in a shelter. The investigators will identify patient presentations as being due to opioid poisoning, opioid dependence, or polysubstance use to subgroup the cohort for our assessment of patients' risk profile in pre-planned subgroup analyses. The investigators will apply the following standardized definitions and refine them, if needed, to achieve high between-rater agreement between research assistants and physicians:1) Opioid poisoning. The investigators define opioid poisoning as: (1) historical accounts by EMS personnel, bystanders or the patient of presumed opioid use; and (2) a respiratory rate of \<10 breaths/minute documented in EMS or emergency department records or reported by bystanders in the context of decreased level of consciousness.30,35,36 The diagnosis is supported by a known exposure to opioids, but consumption may have been unwitnessed or unintentional (e.g., through contamination of another substance with fentanyl). Miosis (small pupils) and hypoxia (low blood oxygen levels) are often but not always present. The diagnosis is supported by known exposure to opioids, but consumption may have been unwitnessed or unintentional (e.g., contamination of another drug). Miosis (small pupils) and hypoxemia (low blood oxygen) are often but not always present. Breathing improves after naloxone administration or a period of observation. If treatment was delayed, the patient may suffer cardiac arrest and/or brain injury from low blood oxygen. There was no obvious alternative cause (e.g., head trauma) to explain the patient's presentation. Research assistants will document whether clinicians implied that the patient experienced opioid poisoning or intoxication in the medical record, in the absence of the definition being met. 2) Opioid dependence. Patients with opioid dependence experience withdrawal symptoms (see below) after opioid use. Patients with withdrawal symptoms, a documented diagnosis of opioid use disorder in the list of ED discharge diagnoses or as a comorbidity in clinician notes, and/or an active prescription for OAT at the index visit would be classified as a patient with opioid dependence. Research assistants will document whether clinicians implied that the patient has opioid dependence in the medical record, in the absence of the definition being met.3) Opioid withdrawal. The investigators define opioid withdrawal as the documentation of any of the following in the medical record: new or worsening nausea requiring treatment, new or worsening agitation, aggressive behavior towards staff, restlessness, heart rate >100 beats per minute, diarrhea, tremor, flushing, sweating, piloerection (gooseflesh skin), bone or joint aches, rhinorrhea, lacrimation, or yawning, or documentation of a score >5 on the Clinical Opioid Withdrawal Score scale, which has been incorporated into medical records at many sites and validated for use by emergency nurses. Precipitated withdrawal occurs within 1h of naloxone or buprenorphine/naloxone administration. Research assistants will document whether clinicians implied the presence of opioid withdrawal in the medical record, in the absence of the definition being met. Outcomes will include: (a) emergency department discharge, (b) leaving against medical advice or without being seen, (c) hospitalization, (d) naloxone administration, (e) provision of a take-home naloxone kit, (f) administration of opioid agonist therapy (methadone, slow release buprenorphine, buprenorphine/naloxone, slow-release oral morphine), (g) consultations, (h) opioid poisoning reversal, (i) opioid withdrawal, (j) in-hospital mortality, and (k) death determined by neurologic criteria. The investigators have planned linkages of registry with administrative data to ascertain (l) retention on opioid agonist therapy, and (m) mortality at 30 and 60-days, and 3 and 12-months. Analysis: The investigators will use summary statistics to describe the patient population, including patient demographics and proxies for Indigeneity, prehospital and emergency department presentation characteristics, and patient outcomes. The investigators will use descriptive statistics to understand the treatments and services provided by EMS and in emergency departments, and to understand the dosing data distribution and the routes of administration of naloxone, as well as the method of buprenorphine/induction used. The investigators will stratify analyses by site characteristics (province, urban/rural, academic/non-academic) and over time to describe practice variation. The investigators will stratify our analyses by sex and gender, as biological sex is a known risk factor for opioid-related mortality, and non-conforming gender (e.g., transgender identity) is associated with health access barriers and poor health outcomes. The investigators will also stratify our analyses using proxies for Indigeneity as the Indigenous population is overrepresented in the patient population affected by the toxic drug crisis and may be treated differently in the ED due to systemic racism. While the proxies for Indigeneity available in medical records are not comprehensive, the VCHRI Indigenous Health Research Unit encouraged us to collect what is available. They or the Indigenous Advisory will guide us in the use and interpretation of these variables. The investigators will assign patients who report staying in a shelter to the shelter's forward sortation area, and those with no fixed address to the forward sortation area of the hospital they presented to.The investigators will derive the clinical decision rule using state-of-the-art methodology. The investigators will pre-define candidate predictor variables based on current knowledge. Sex-at-birth, gender identity, and proxies for Indigeneity will be considered potential predictor variables. The investigators will use multiple imputation for variables with incomplete data (the investigators anticipate \<5% missing data based on prior studies) so all cases can be included. The investigators will assess potential predictor variables for multi-collinearity. The investigators will investigate sex and gender differences, given reported sex and gender-based differences in outcomes through potential interactions with other candidate variables. The investigators will fit logistic regression models and use spline functions for continuous variables. The investigators will then assess the strength of associations using an ANOVA plot to inform how many degrees of freedom to allocate to each variable in the model. The investigators will use a fast stepdown procedure to create a more concise model, then internal bootstrap validation to assess for over-fitting and to calculate optimism. The final reduced model will have points allocated to each variable based on their predictive strength. The investigators will calculate the sensitivity and specificity of the clinical decision rule, along with discrimination and calibration of regression-based risk scores. The investigators will present the performance of the derived rule using each patient's total point score and predicted risk category (low, medium, high) as follows: (a) discrimination between cases that experience the outcome of interest or not, using the area under the receiver operating curve with 95% CIs; (b) calibration by graphically comparing the observed and expected probabilities of outcomes for each level of the score, and the Hosmer-Lemeshow χ2 goodness-of-fit statistic; and (c) classification performance of the scoring system and risk categories using 95% CIs for sensitivity, specificity, and predictive values. A Knowledge Translation committee will ensure our work remains relevant and impactful to knowledge users and patients by employing effective strategies refined to support the dissemination of findings from the study. Patients with lived/living experience and Indigenous Advisory will continue to help refine research questions, variables, screening procedures and outcomes. The investigators plan to present our results back to them, to assist with interpretation of our findings. Knowledge users include CanadiEM (generate infographics), Emergency Care BC (provincial health improvement network), the Canadian Association of Emergency Physicians (national rounds), and Public Health and Poison Centre collaborators who will facilitate translation of our work into practice. Others will engage with us via emails, briefing notes, and in presentations and webinars. The investigators will seek guidance from the Indigenous Advisory Committee on who should receive findings to ensure they reach Indigenous Peoples, including non-academic healthcare providers. The investigators will develop simple, accessible knowledge translation materials to support patients in emergency settings.

03

Conditions studied

  • Opioid Use Disorder
  • Opioid Abuse or Dependence
  • Opioid Withdrawal
  • Polysubstance Drug Use (Indiscriminate Drug Use)
  • Polysubstance Abuse

Keywords

  • Opioid use disorder
  • Opioid poisoning
  • CEDRN Opioid Registry
  • Opioid dependence
  • polysubstance abuse
  • polysubstance drug use
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients presenting to any one of the Canadian Emergency Department Research Network's emergency department, and meeting the inclusion criteria.

Eligibility criteria

Inclusion Criteria:

  1. All patients who arrive at the emergency department with the following emergency department discharge diagnosis:

    • Percocet Overdose
    • Oxycontin Overdose
    • Oxycodone Overdose
    • Opioid Overdose or Intoxication
    • Methadone Overdose
    • Heroin Overdose
    • Fentanyl Overdose
    • Codeine Overdose
    • Carfentanil Overdose
    • Opioid Withdrawal
  2. All patients who arrive at the emergency department who had the following medication ordered in the present visit or previous hospital visits in the past 2 years:

    • Buprenorphine
    • Buprenorphine-naloxone
    • Methadone - Past ED or IP encounter
    • Kadian/Morphine long-acting
    • Naloxone
    • Naloxone kit
  3. All patients who arrive at the emergency department with the following impatient discharge diagnosis:

    • Opioid use disorder (mild/moderate/severe, abuse/dependence), or opioid-related disorders
    • Adverse effect, and poisoning by polysubstance use
    • Opioid intoxication or withdrawal
    • Intoxication or withdrawal (from any substance, including unspecified ones)
    • Adverse effect, and poisoning by opioids, benzodiazepines, other antiepileptic and sedative-hypnotic drugs, and unspecified drugs
    • Any psychoactive substance abuse resulting in intoxication, withdrawal, or any adverse effects
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
7,200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Proportion of patients who received opioid agonist therapy (methadone, buprenorphine/naloxone, extended release buprenorphine injection, slow-release oral morphine).

    Number of patients that were administered any of the following types of opioid agonist therapy during their visit to the emergency department.

    Time frame: From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

Other outcomes

  1. Proportion of patients who left against medical advice.

    Percentage of patient leave before being formally discharged from the emergency department, or leaving the emergency department without being seen by a physician.

    Time frame: From date of emergency department arrival date until date and time of first documented "leaving against medical advice" or "leaving without being seen" or other similar terms in patient's medical chart (within the first 72 hours since arrival).

  2. Proportion of patients hospitalized

    Whether the patient was admitted to the hospital after their emergency department visit

    Time frame: From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

  3. Proportion of naloxone administration

    Was patient administered during their emergency department visit

    Time frame: From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

  4. Proportion of in-hospital mortality

    Number of patients who died in the hospital

    Time frame: From date of arrival until the date of first hospital documented date of death from any cause (assessed up to 30 days since emergency department arrival).

  5. Proportion of patients with opioid withdrawal while in the emergency department

    Whether the patient experienced opioid withdrawal while in the emergency department

    Time frame: From date of emergency department arrival date until they are discharged from the emergency department (usually within the first 72 hours since arrival time).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kaczorowski J, Bilodeau J, M Orkin A, Dong K, Daoust R, Kestler A. Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review. Acad Emerg Med. 2020 Nov;27(11):1173-1182. doi: 10.1111/acem.14054. Epub 2020 Jul 28. PubMed 32557932 ↗
  • Chen Y, Wang Y, Nielsen S, Kuhn L, Lam T. A systematic review of opioid overdose interventions delivered within emergency departments. Drug Alcohol Depend. 2020 Aug 1;213:108009. doi: 10.1016/j.drugalcdep.2020.108009. Epub 2020 May 23. PubMed 32580113 ↗
  • D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1636-44. doi: 10.1001/jama.2015.3474. PubMed 25919527 ↗
  • Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, Brasher P, Gill S, Garrod E, Bath M, Kestler A. Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study. J Am Coll Emerg Physicians Open. 2020 Oct 20;1(6):1712-1722. doi: 10.1002/emp2.12289. eCollection 2020 Dec. PubMed 33392580 ↗
  • Moe J, Chong M, Zhao B, Scheuermeyer FX, Purssell R, Slaunwhite A. Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis. CMAJ Open. 2021 Mar 17;9(1):E242-E251. doi: 10.9778/cmajo.20200169. Print 2021 Jan-Mar. PubMed 33731425 ↗
  • Zhang X, Wang N, Hou F, Ali Y, Dora-Laskey A, Dahlem CH, McCabe SE. Emergency Department Visits by Patients with Substance Use Disorder in the United States. West J Emerg Med. 2021 Aug 19;22(5):1076-1085. doi: 10.5811/westjem.2021.3.50839. PubMed 34546883 ↗
  • Beckerleg W, Hudgins J. Substance Use-related Emergency Department Visits and Resource Utilization. West J Emerg Med. 2022 Feb 28;23(2):166-173. doi: 10.5811/westjem.2022.1.53834. PubMed 35302449 ↗
  • Mok V, Brebner C, Yap J, Asamoah-Boaheng M, Hutton J, Haines M, Scheuermeyer F, Kawano T, Christenson J, Grunau B. Non-prescription drug-associated out-of-hospital cardiac arrest: Changes in incidence over time and the odds of receiving resuscitation. Resuscitation. 2024 Feb;195:110107. doi: 10.1016/j.resuscitation.2023.110107. Epub 2023 Dec 30. PubMed 38160902 ↗
  • Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. Ann Emerg Med. 2021 Sep;78(3):434-442. doi: 10.1016/j.annemergmed.2021.04.023. Epub 2021 Jun 23. PubMed 34172303 ↗
  • Gomes T, Kitchen SA, Murray R. Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. JAMA Netw Open. 2021 May 3;4(5):e2112865. doi: 10.1001/jamanetworkopen.2021.12865. PubMed 34037734 ↗
  • Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, Tadrous M, Munro C, Antoniou T, Werb D, Wyman J. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA. 2022 Mar 1;327(9):846-855. doi: 10.1001/jama.2022.1271. PubMed 35230394 ↗
  • Fischer B. The continuous opioid death crisis in Canada: changing characteristics and implications for path options forward. Lancet Reg Health Am. 2023 Feb 3;19:100437. doi: 10.1016/j.lana.2023.100437. eCollection 2023 Mar. No abstract available. PubMed 36950034 ↗
  • Nguyen T, Buxton JA. Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework. Int J Drug Policy. 2021 Jul;93:103236. doi: 10.1016/j.drugpo.2021.103236. Epub 2021 Mar 20. PubMed 33838990 ↗

Individual participant data

Plan to share: No — Data is only available for CEDRN members. Non-member researchers interested in using any CEDRN data must be voted in by the CEDRN Executive Committee. For more information, please inquire https://cedrn.ca/collaborate/

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2030, 60 months after the start.

Of 74 non-industry observational studies under Opioid-Related Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 60 months is above that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Mar 12, 2026
StartActual
Jul 24, 2025
Primary completionEst.
Jul 24, 2030
CompletionEst.
Dec 31, 2030
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07466784
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Corinne Hohl (Professor and Head, Department of Emergency Medicine at UBC, University of British Columbia) — Principal investigator
First posted
Mar 12, 2026
Start date
Jul 24, 2025
Primary completion
Jul 24, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 12, 2026

Study contacts

Jeffrey P Hau, MSc
Contact
jeffrey.hau@ubc.ca
16048754111
Vi Ho, MD
Contact
vi.ho@ubc.ca
6048754111
Corinne M Hohl, MD, MPH
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion